CTOs on the Move

Medizone International

www.medizoneint.com

 
Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices. The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets, through its expanding distributor network. The ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.medizoneint.com
  • 350 East Michigan Avenue Suite 500
    Kalamazoo, MI USA 49007
  • Phone: 269.202.5020

Executives

Name Title Contact Details

Similar Companies

TetraGenx

TetraGenx is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Suvoda

Suvoda’s sole focus is to offer the industry’s leading SaaS solution for randomization and trial supply management. Suvoda’s Interactive Response Technology (IRT/IWRS) combines the flexibility of a custom solution with the speed of a configurable platform, offering 4-week deployment, reimagined reporting, and easy integration.

Eupraxia Pharmaceuticals

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.

PharmaLeaders

PharmaLeaders is a Conshohocken, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novocure

We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, Novocure has offices in Germany, Switzerland, Japan and Israel.